Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-

Internal Medicine

Volumn 51, Issue 17, 2012, Pages 2337-2340

  Sano, Makoto ^a   Saotome, Masao ^a   Urushida, Tsuyoshi ^a   Katoh, Hideki ^a   Satoh, Hiroshi ^a   Ohnishi, Kazunori ^a   Hayashi, Hideharu ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic myeloid leukemia; Dasatinib; Pulmonary arterial hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DASATINIB; NILOTINIB; SILDENAFIL;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DOPPLER ECHOCARDIOGRAPHY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLE OVERLOAD; HUMAN; P WAVE; PERICARDIAL EFFUSION; PULMONARY HYPERTENSION; R WAVE; SYSTOLIC BLOOD PRESSURE; T WAVE INVERSION; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION;

ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PURINES; PYRIMIDINES; SULFONES; THIAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS; WITHHOLDING TREATMENT;

EID: 84867824824     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7472     Document Type: Article

References (21)

1. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25: 3908-3914, 2007.
2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers), endorsed by the international society of heart and lung transplantation (ishlt). Eur Heart J 30: 2493-2537, 2009.
3. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. Cancer 98: 2636-2642, 2003.
4. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541, 2006.
5. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010.
6. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted cml patient. Bone Marrow Transplant 43: 967-968, 2009.
7. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36: e4-e6, 2012.
8. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11: 30, 2011.
9. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38: 218-220, 2011.
10. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33: 861-864, 2009.
11. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125: 2128-2137, 2012.
12. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353: 1412-1413, 2005.
13. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: Current therapeutic strategies. Nat Clin Pract Cardiovasc Med 4: 319-329, 2007.
14. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61: 736, 2006.
15. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by pdgf inhibition. J Clin Invest 115: 2811-2821, 2005.
16. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88, 2008.
17. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182: 1171-1177, 2010.
18. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 3: 89-101, 2009.
19. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the bcr-abl inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063, 2007.
20. Oda Y, Renaux B, Bjorge J, Saifeddine M, Fujita DJ, Hollenberg MD. Csrc is a major cytosolic tyrosine kinase in vascular tissue. Can J Physiol Pharmacol 77: 606-617, 1999.
21. Pullamsetti SS, Berghausen EM, Dabral S, et al. Role of src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32: 1354-1365, 2012.